Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 1
2001 1
2002 7
2003 8
2004 16
2005 10
2006 28
2007 30
2008 39
2009 52
2010 57
2011 54
2012 79
2013 86
2014 115
2015 129
2016 123
2017 115
2018 165
2019 173
2020 229
2021 261
2022 297
2023 252
2024 223

Text availability

Article attribute

Article type

Publication date

Search Results

2,248 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: yang f. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, Lu J, Li X, Gao Y, Lei L, Liu J, Li J; ESPRIT Collaborative Group. Liu J, et al. Lancet. 2024 Jul 20;404(10449):245-255. doi: 10.1016/S0140-6736(24)01028-6. Epub 2024 Jun 27. Lancet. 2024. PMID: 38945140 Clinical Trial.
Biomedical Application of Decellularized Scaffolds.
Zhang F, Gao H, Jiang X, Yang F, Zhang J, Song S, Shen J. Zhang F, et al. Among authors: yang f. ACS Appl Bio Mater. 2023 Dec 18;6(12):5145-5168. doi: 10.1021/acsabm.3c00778. Epub 2023 Nov 30. ACS Appl Bio Mater. 2023. PMID: 38032114 Review.
The Mechanisms of Sevoflurane-Induced Neuroinflammation.
Huang X, Ying J, Yang D, Fang P, Wang X, Zhou B, Zhang L, Fang Y, Yu W, Liu X, Zhen Q, Hua F. Huang X, et al. Among authors: fang y. Front Aging Neurosci. 2021 Aug 5;13:717745. doi: 10.3389/fnagi.2021.717745. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34421578 Free PMC article. Review.
Rice SUT and SWEET Transporters.
Hu Z, Tang Z, Zhang Y, Niu L, Yang F, Zhang D, Hu Y. Hu Z, et al. Among authors: yang f. Int J Mol Sci. 2021 Oct 18;22(20):11198. doi: 10.3390/ijms222011198. Int J Mol Sci. 2021. PMID: 34681858 Free PMC article. Review.
Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
Zhao J, Yuan F, Song C, Yin R, Chang M, Zhang W, Zhang B, Yu L, Jia Y, Ma Y, Song Y, Wang C, Song C, Wang X, Shang L, Yang F, Jiang W; OPENS Trial Investigators. Zhao J, et al. Among authors: yang f. Lancet Neurol. 2022 Apr;21(4):319-328. doi: 10.1016/S1474-4422(22)00010-2. Epub 2022 Feb 24. Lancet Neurol. 2022. PMID: 35219379 Clinical Trial.
The progress of pulmonary artery denervation.
Xie Y, Liu N, Xiao Z, Yang F, Zeng Y, Yang Z, Xia Y, Chen Z, Xiao Y. Xie Y, et al. Among authors: yang f. Cardiol J. 2022;29(3):381-387. doi: 10.5603/CJ.a2020.0186. Epub 2021 Jan 13. Cardiol J. 2022. PMID: 33438182 Free PMC article. Review.
2,248 results